FT
Flare TherapeuticsFlare Therapeutics is a clinical-stage biotech developing small-molecule drugs that target transcription factors, including a first-in-class ARON-targeting degrader for prostate cancer.
2 Pulse stories
OB
Ollin BiosciencesClinical-stage biopharmaceutical company developing best-in-disease therapies for vision-threatening eye diseases, including a VEGF/Ang2 bispecific antibody in Phase 3 for DME and wet AMD.
2 Pulse stories
Total Raised
$290M
$430M
Flare TherapeuticsOllin Biosciences
Last ValuationNot disclosed
Biotech
Sector
Biotech
2021
Founded
2023
Cambridge, Massachusetts
HQ
Chicago, Illinois
Private
Status
Private
Flare Therapeutics investors
Third Rock VenturesNextech InvestPfizer VenturesBoxer CapitalGordonMD Global InvestmentsInvusCasdin CapitalEli Lilly and Company
Ollin Biosciences investors
ARCH Venture PartnersTCGX (TCG Crossover)Andreessen HorowitzMubadala CapitalMonograph CapitalBlackstone Multi-Asset InvestingCommodore CapitalRA Capital Management
Data from Value Add Pulse coverage and company research — see the full threads for Flare Therapeutics and Ollin Biosciences.